Morphea Clinical Trial
Official title:
Something New Under the Sun: A Randomized, Double-Blinded, Controlled Trial of UVA1 Phototherapy in Morphea
This is a randomized, blinded, and controlled trial to assess the efficacy and safety of UVA1
phototherapy in the treatment of active morphea in adults and children. Forty patients will
be randomized to receive either medium dose (70 J/cm2) phototherapy (active UVA1
phototherapy) with an ultraviolet translucent acrylic screen or "sham" UVA1 (0 J/cm2)
phototherapy with an ultraviolet opaque acrylic screen 3 times per week for 10 weeks. The
phototherapists, patients, and principal investigator will be blinded to whether the patients
receive active or sham UVA1 phototherapy. Patients will only be allowed to apply emollients
during the study.
Patients completing the randomized placebo controlled trial (RPCT) will be followed during an
open observation period for 3 months. During the open phase, all outcome measures from the
RPCT (LoSSI, PGA-A) will be assessed every 5 weeks as well as adverse events. Patients who
received sham UVA1 phototherapy will be invited to receive active UVA1 phototherapy using the
same protocol as in the RPCT during the open observation. Adult patients enrolled in the RPCT
will also be part of a nested translational study investigating the effect of UVA1
phototherapy on gene expression from whole skin biopsies taken before (Study Visit 1) and
after UVA1 phototherapy (Study Visit 3). Gene expression profiles will be compared in
lesional skin before and after treatment as well as nonlesional skin.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03351114 -
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
|
Phase 2 | |
| Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
| Withdrawn |
NCT00230373 -
Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
|
Phase 3 | |
| Recruiting |
NCT01808937 -
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
|
||
| Terminated |
NCT02411643 -
Molecular Effects of Topical Calcipotriene on Morphea
|
Early Phase 1 | |
| Enrolling by invitation |
NCT04922736 -
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
|
N/A | |
| Withdrawn |
NCT04656704 -
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
|
Early Phase 1 | |
| Completed |
NCT04752397 -
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
|
||
| Terminated |
NCT03740724 -
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
|
Phase 1/Phase 2 | |
| Completed |
NCT02222038 -
Genetic Variants in Linear Localized Scleroderma
|
N/A |